Modernizing clinical trial eligibility criteria: Recommendations of the American society of clinical oncology-friends of cancer research HIV working group

Journal of Clinical Oncology

Volumn 35, Issue 33, 2017, Pages 3774-3780

  Uldrick, Thomas S ^a   Ison, Gwynn ^b   Rudek, Michelle A ^c   Noy, Ariela ^d   Schwartz, Karl ^e   Bruinooge, Suanna ^f   Schenkel, Caroline ^g   Miller, Barry ^b   Dunleavy, Kieron ^g   Wang, Judy ^h   Zeldis, Jerome ⁱ   Little, Richard F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Patients Against Lymphoma   (United States)

^f ASCO   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h Florida Cancer Specialists   (United States)

ⁱ SORRENTO THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ANTIRETROVIRAL THERAPY; ARTICLE; CANCER PATIENT; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); DRUG RESEARCH; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE STATUS; MEDICAL SOCIETY; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PATHOGENICITY; PROCEDURES; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; ELIGIBILITY DETERMINATION; HIV; HIV INFECTIONS; HUMANS; UNITED STATES;

EID: 85034438079     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.7338     Document Type: Article

References (23)

1. Samji H, Cescon A, Hogg RS, et al: Closing the gap: Increases in life expectancy among treated HIVpositive individuals in the United States and Canada. PLoS One 8:e81355, 2013
2. Lewden C, Bouteloup V, De Wit S, et al: Allcause mortality in treated HIV-infected adults with CD4 $500/mm3 compared with the general population: Evidence from a large European observational cohort collaboration. Int J Epidemiol 41: 433-445, 2012
3. Centers for Disease Control and Prevention: HIV in the United States: At a glance. http://www.cdc. gov/hiv/statistics/overview/ataglance.html
4. WHO: Global Health Observatory data, HIV/AIDS, 2016. http://www.who.int/gho/hiv/en
5. Lee FJ, Amin J, Carr A: Efficacy of initial antiretroviral therapy for HIV-1 infection in adults:Asystematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up. PLoS One 9:e97482, 2014
6. Department of Health andHuman Services Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/ contentfiles/lvguidelines/AdultandAdolescentGL.pdf
7. WHO: Treat all people with HIV, offer antiretrovirals as additional prevention choice for people at "substantial" risk. http://www.who.int/mediacentre/ news/releases/2015/hiv-treat-all-recommendation/en/
8. WHO: Global AIDS response progress reporting (WHO/UNICEF/UNAIDS): Global health observatory visualizations, HIV/AIDS response: Actual and projected number of people receiving ART in LMICs, by WHO region, 2013. http://apps.who.int/ gho/data/node.wrapper.HIV1-1-1?lang=en
9. Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753-762, 2011
10. Vandenhende MA, Roussillon C, Henard S, et al: Cancer-related causes of death among HIVinfected patients in France in 2010: Evolution since 2000. PLoS One 10:e0129550, 2015
11. Silverberg MJ, Lau B, Achenbach CJ, et al: Cumulative incidence of cancer among persons with HIV in North America: A cohort study. Ann Intern Med 163:507-518, 2015
12. Engels EA, Biggar RJ, Hall HI, et al: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187-194, 2008
13. Uldrick TS, Little RF: How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood 125:1226-1235, 2015
14. Dunleavy K, Little RF, Pittaluga S, et al: The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 115:3017-3024, 2010
15. Dunleavy K, Pittaluga S, Shovlin M, et al: Lowintensity therapy in adults with Burkitt's lymphoma. N Engl J Med 369:1915-1925, 2013
16. Montoto S, Shaw K, Okosun J, et al: HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 30:4111-4116, 2012
17. D'Jaen GA, Pantanowitz L, Bower M, et al: Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: A multi-institutional collaboration. Clin Lung Cancer 11:396-404, 2010
18. Alvarnas JC, Le Rademacher J, Wang Y, et al: Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803/AMC 071 trial. Blood 128:1050-1058, 2016
19. Persad GC, Little RF, Grady C: Including persons with HIV infection in cancer clinical trials. J Clin Oncol 26:1027-1032, 2008
20. Wijermans PW, Gerrits WB, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292-296, 1993
21. Chakrabarti S, Mackinnon S, Chopra R, et al: High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 99:4357-4363, 2002
22. Panel on Opportunistic Infections in HIVInfected Adults and Adolescents: Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/ lvguidelines/adult-oi.pdf
23. Rudek MA, Flexner C, Ambinder RF: Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet 12:905-912, 2011